Key result
Exposure of human cardiomyocytes to /ml of advanced glycation end products reduced cell viability to 44% and altered the expression of key cardiac biomarkers including MHC and Cx-43.
Why the study?
To elucidate the impact of advanced glycation end products and glucose shock on cardiomyocyte viability, gene expression, cardiac biomarkers, and cardiac contractility.
Does exposure to AGEs and glucose shock affect cardiomyocyte viability, gene expression, and contractility in an in-vitro model?
Does exposure to AGEs and glucose shock affect cardiomyocyte viability, gene expression, and contractility in an in-vitro model?
Exposure to AGEs and glucose shock alters cardiomyocyte viability, gene expression, and contractility, providing insights into the mechanisms of diabetic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May implicate AGEs in diabetic cardiomyopathy; leaves open clinical relevance pending in vivo and human validation.
This study aimed to elucidate the impact of advanced glycation end products (AGEs) and glucose shock on cardiomyocyte viability, gene expression, cardiac biomarkers, and cardiac contractility. Firstly, AGEs were generated in-house, and their concentration was confirmed using absorbance measurements. AC16 cardiomyocytes were then exposed to varying doses of AGEs, resulting in dose-dependent decreases in cell viability. The maximum tolerated dose of AGEs was determined, revealing significant downregulation of the cardiac gene gap junction alpha 1 (GJA1). Furthermore, the study assessed the effects of AGEs, glucose shock, and their combination on biomarkers, cardiac myosin heavy chain (MHC) and connexin-43 (Cx-43), in AC16 cells. It was found that AGEs supplementation induced an increase in MHC expression while reducing Cx-43 expression, potentially contributing to cardiac dysfunction. Glucose shock also affected cardiomyocyte contractility, highlighting the complex interplay between AGEs, glucose levels, and cardiac function. Additionally, human iPSC-derived cardiomyocytes were subjected to varying doses of AGEs, revealing dose-dependent cytotoxicity and alterations in contractility. Immunostaining confirmed upregulation of MYH7, a cardiac gene associated with muscle contraction, in response to AGEs. However, the expression of Cx-43 was minimal in these cells. This investigation sheds light on the intricate relationship between AGEs, glucose shock, and cardiomyocyte function, providing insights into potential mechanisms underlying cardiac dysfunction associated with metabolic disorders such as diabetic cardiomyopathy (DCM). Supplementary Information: The online version contains supplementary material available at 10.1007/s42452-025-07442-y.
No takes yet. Share an insight, caveat, or question.
Hernandez et al. (2025) studied Diabetic cardiomyopathy (in-vitro model). Advanced glycation end products (AGEs) and glucose shock vs. Untreated control cells was evaluated on Cell viability of AC16 cardiomyocytes at 24 hours. Exposure of human cardiomyocytes to /ml of advanced glycation end products reduced cell viability to 44% and altered the expression of key cardiac biomarkers including MHC and Cx-43.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: